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PENGENALPASTIAN HYDRALAZIN SEBAGAI SEBATIAN ANTI-
JANGKITAN Pseudomonas aeruginosa DENGAN MODEL C. elegans   
ABSTRAK 
Lisozim adalah model enzim yang penting dalam bidang penyelidikan 
bioperubatan. Sehubungan dengan taburan meluas dalam pelbagai tisu dan rembesan, 
lisozim dikenali dengan fungsi sebagai enzim pertahanan anti-bakteria manakala 
fungsi sampingan sebagai enzim pencernaan juga dilaporkan dalam segelintiran taksa. 
Antara keluarga lisozim C. elegans, fungsi lys-7 telah dilaporkan dengan kepentingan 
imun dalam mekanisma penentangan terhadap jangkitan P. aeruginosa. Dengan 
menggunakan gabungan kaedah penyaringan kandungan tinggi berpandukan imej dan 
model jangkitan berasaskan C. elegans – patogen, sebanyak 15, 629 sebatian molekul 
kecil telah disaring dalam usaha pencarian calon pemodulat imun lys-7 sebagai anti-
jangkitan. Ini juga merupakan laporan pertama bahawa kajian penyaringan kandungan 
tinggi yang berasaskan lys-7::GFP. Saya mengenalpasti hydralazin sebagai molekul 
kecil yang mampu meningkatkan daya penentangan C. elegans terhadap jangkitan P. 
aeruginosa tanpa menjejaskan kebolehhidupan dan penghasilan faktor kevirulenan 
bakteria. Saya juga merungkaikan mekanisma hydralazin sebagai anti-jangkitan ini 
memerlukan laluan isyarat biologi seperti Insulin/Factor Pertumbuhan-1 bak insulin 
(IGF-1) dan Faktor Pertumbuhan Transformasi- β (TGF-β). Saya juga membuktikan 
bahawa rawatan awal dengan hydralazin dapat meningkatkan daya penentangan C. 
elegans terhadap jangkitan P. aeruginosa. Selain itu, hydralazin juga menunjukkan 
spektrum bioaktiviti yang luas dengan keupayaan merangsangkan daya hidup C. 
elegans semasa jangkitan patogen Enterococcus faecalis dan Salmonella typhimurium. 
Kajian ini menunjukkan ketersauran penyaringan secara fenotaip yang berpandukan 
imej untuk penemuan sebatian anti-jangkitan.   
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IDENTIFICATION OF HYDRALAZINE AS AN ANTI-INFECTIVE 
COMPOUND IN Pseudomonas aeruginosa-INFECTED C. elegans 
ABSTRACT 
Lysozymes are important enzyme models with biomedical importance. In 
accordance with its widespread distribution in various biological tissues and secretions, 
lysozyme is implicated primarily in the antibacterial defense, although an additional 
function as digestive enzyme has been described as well for several taxa. Using a 
combination of image-based high-content screening and C. elegans - pathogen 
infection model, I screened a total of 15,629 small molecule compound to isolate 
potential immunomodulators of lys-7, an immune effector implicated in C. elegans 
innate immunity during microbial infection. I reported this as the first lys-7::GFP based 
phenotypic high-throughput screening assay. I identified hydralazine as a small 
molecule capable of promoting C. elegans resistance towards Pseudomonas 
aeruginosa infection without affecting bacterial cell viability and virulence factor 
production.  I delineated that this protective mechanism was mediated by the 
evolutionarily conserved signaling pathways of insulin/insulin-like growth factor 1 
(IGF-1) and Transforming Growth Factor-β (TGF-β). I also further provided evidence 
that early stimulation of the host immune response by hydralazine could confer a 
survival advantage to C. elegans during infection.  Remarkably, this 
immunostimulating compound also protected C. elegans from Enterococcus faecalis 
and Salmonella typhimurium infection, suggesting the broad spectrum bioactivity of 
hydralazine. This study demonstrated the feasibility of using an image-based 
phenotypic screen to search for small molecules with potential anti-infective properties.  
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CHAPTER 1 
INTRODUCTION 
1.1 Research background 
The unprecedented emergence of multidrug resistant bacteria had urged the 
search for novel approaches to address current unmet medical needs. The rapid 
widespread of multidrug resistant strains had rendered most antibiotics, such as 
aminoglycosides, cephalosporins, fluoroquinolones and carbapenems ineffective 
against infection (Centers for Disease Control and Prevention, 2013). Thus, the 
development of anti-infective that capitalizes on the mechanism targeting host 
immunity or pathogen virulence factor could be a conceivable strategy in combating 
these antimicrobial-resistant infections (Bhavsar & Brown, 2006; Pirofski & 
Casadevall, 2006; Hamill et al, 2008). Without affecting microbial viability, anti-
infective imposes weaker selection pressure and reduces the emergence of resistant 
strains (Clatworthy et al, 2007; Hancock et al, 2012; Arvanitis, 2013).  
Caenorhabditis elegans is first proposed as model organism to study 
development and neurobiology by Sydney Brenner in 1960’s (Brenner, 1974).  Since 
then, this nematode has become a principal model organism in biological research such 
as ageing (Kenyon et al, 1993), genetic study, cell lineage mapping (Sulston & Horvitz, 
1977) and more recently in innate immunity studies (Tan et al, 1999; Kaletta et al, 
2006). This genetically tractable and amendable model organism offers an excellent 
screening tool for pharmacology-related agents. The microscopic size of C. elegans 
also permits a high-throughput screening manner in a whole-animal context and this 
high screening capacity is not achievable by using traditional mammalian models due 
to the enormous costs and ethical constraints (Arvanitis et al, 2013). With the 
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surprisingly high degree conservation of biochemical pathways between C. elegans 
and human, the study of C. elegans innate immunity yields valuable biology insights 
into molecular basis and advances the understanding towards the higher organisms.   
Pseudomonas aeruginosa is a clinically important pathogen responsible for 
nosocomial infection and infamous for the arising morbidity, mortality and healthcare 
costs worldwide. The multidrug resistance of P. aeruginosa poses great challenges to 
the healthcare community and this problem is worsen by the bottleneck faced by the 
pharmaceutical industries in developing new drugs combating this infectious agent. 
The clinical isolate of P. aeruginosa UCBPP-PA14 (hereafter annotated as PA14) is 
identified as multi-host pathogen capable to infect mouse, plants and insects (Rahme 
et al, 1995). PA14 is thus commonly used as reference strain as this highly virulent 
strain affords for a wide host spectrum for studies of virulence mechanisms (Mahajan-
Miklos et al, 2000). Following the establishment of C. elegans – pathogen infection 
model (Tan et al, 1999), C. elegans are reported to be susceptible to a number of human 
pathogens including P. aeruginosa and it appears that the genetic factors involved in 
the mammalian pathogenesis are also required for C. elegans model (Marsh and May, 
2012). Particularly, I focus my study on lysozyme, an immune effector implicated in 
C. elegans defense during P. aeruginosa infection. Lysozyme was first described in 
chicken egg white (Laschtschenko 1909) but was not officially named for its lytic 
bioactivity until 1922 by Alexander Fleming (Fleming 1922). Following then, a wide 
range of research were performed on lysozyme, including protein structure study 
(Blake et al. 1965, Phillips, 1967), the use of lysozyme as disease marker for diagnostic 
purpose (Osserman & Lawlor 1966; Glynn, 1968; Pruzanski & Saito, 1969), the 
enzymatic function of lysozyme (Jolles & Jolles, 1984), protein binding (Baniahmad 
et al. 1991; Madhusudan & Vijayan 1992; Bonifer et al, 1997) and lysozyme gene 
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regulation (Short et al, 1996). Of note, owing to its bacteriolytic characteristic to 
hydrolyze 1,4-β-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine 
residues within peptidoglycan, lysozyme is implicated as an important immune 
defense effector against bacterial infection (Jolles & Jolles, 1984). More recently, the 
host-pathogen interaction studies using C. elegans as infection model has revealed the 
importance of lysozymes in pathogen resistance (Mallo et al, 2002; Evans et al, 2008; 
Kurz & Ewbank, 2003; Marsh et al, 2011). Of note, Evans et al (2008) described PA14 
unique virulence mechanisms to overcome C. elegans host immune defense by 
suppressing lysozyme (lys-7, specifically) expression. Thus, the search for such 
lysozyme modulating agent would be interesting to investigate if such modulating 
agent could be used as anti-infective to promote host resistance against infection.        
Although lysozyme has been intensively studied over the decades, only few 
research had been done in the search for lysozyme modulating agents from crude 
extracts or semi-purified natural products. Most of these works were performed by 
using laborious experimental procedures with limited screening throughput (Zhou et 
al, 2011; Dharmalingam et al, 2012; Kandasamy et al, 2012; Kong et al, 2014). With 
the increasing needs for therapeutic products, it is imperative to employ innovative 
methodologies to improve the robustness, efficacy and sensitivity of a screening assay 
in the search for relevant compounds.  
Thus, this work describes an image-based high-content screening for lysozyme 
immunomodulating agents, with P. aeruginosa selected as the representative pathogen 
to evaluate the potential of small molecules as efficacious anti-infectives. Ultimately, 
this strategy could discover novel therapeutics in addressing the fundamental 
challenges in drug development.      
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1.2 Aim of the study   
 Recognizing the biomedical importance of lysozyme, I aim to perform a high-
throughput screening assay for lysozyme immunomodulating compounds. I 
hypothesize that a lysozyme immunostimulating compound could be used as an anti-
infective agent to mediate host immune response and promote host resistance towards 
pathogen infection.  
To achieve these goals, this thesis examines the following objectives: 
1. To establish an automated, image-based screening assay in 384-well 
microplate format by using lys-7::GFP transgenic C. elegans as screening 
subject. 
2. To perform a high-content screening of small molecule chemical libraries 
containing ~16, 000 compounds to identify candidates that induce C. elegans 
lys-7 GFP expression. 
3. To examine lys-7 stimulating compound efficacy as anti-infective using C. 
elegans – P. aeruginosa survival assay. 
4. To perform preliminary mode-of-action study of immunostimulating 
compound by investigating the involvement of signaling pathways in 
mediating compound-induced lys-7 expression. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Antibiotic resistance 
 The discovery of penicillin by Sir Alexander Fleming in 1928 was recognized 
as one of the major advances in human medical history. Since then, the antimicrobial 
drug development had been actively pursued for this wonder drug to treat various 
infectious diseases. Different classes of antibiotics target the essential physiological 
and biochemical processes within bacteria to achieve antimicrobial activity, such as 
the interference of bacterial cell wall synthesis, cell membrane permeability, DNA and 
RNA synthesis, protein synthesis and folic acid metabolism (Leung, 2011).  
Regrettably, the development of tolerance and resistance in microbial population is 
predictable and inevitable for any antimicrobial compound discovered (Figure 2.1) 
(Davies & Davies, 2010). The antibiotic resistance within microbial community is 
achieved through four main mechanisms i.e.:  the alteration of target site, drug 
inactivation through enzyme-catalyzed destruction, the reduction of drug 
bioaccumulation (through active efflux pumps or decreasing drug permeability) and 
alteration of metabolic pathway (Leung, 2011). In addition to this immunity and 
bypass, the microbial intrinsic characteristic (by genetic mutations) and acquired 
resistance traits (via horizontal genetic transfer) exacerbated the rapid widespread of 
antibiotic resistance among microbial community.  
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Figure 2.1: The timeline of antibiotic discovery (depicted above timeline) and the 
timeline when the antibiotic resistance was first reported (depicted below timeline). 
(Source: Clatworthy et al, 2007) 
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The emergence of multidrug resistant bacteria strains is an alarming threat to 
public health as these microbes are resilient towards most antibiotic treatments, 
impairing the effectiveness of antimicrobial chemotherapy. The pipeline for new 
effective antibacterial agents would be endless as a successful treatment of infection 
requires effective antibiotic therapy and yet the antibiotic resistance emerged at a faster 
pace than it can be controlled. With only 22 new antibiotics discovered since 2000 
(Figure 2.2), the declining number of approved antimicrobial drugs in recent decades 
had been a worrisome concern (Butler et al, 2013). Apart from the long timescale 
required for drug development, the disengagement of most pharmaceutical companies 
from antimicrobial research due to risks-and-benefits consideration and regulatory 
challenges further contributed to this unprecedented bottleneck in drug development 
(Carlet et al, 2012). At present, only several large pharmaceutical companies remain 
active in the antibacterial discovery programs, namely GSK, Novartis, AstraZeneca, 
Sanofi-Aventis, Merck and Pfizer, compared to 18 pharmaceutical companies 
registered back in 1990 (Butler et al, 2013).   
It appears that the current drug development for new classes of antibiotics 
could not meet the increasing needs (Clatworthy et al, 2007). Thus, the development 
of novel strategies to combat microbial infectious disease becomes imperative before 
current therapeutic measures dried out, placing the future patients in menace.   
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Figure 2.2: Number of approved antibiotics launched from 2000 to 2012. Only five 
new first-in-class antibiotics have been described, namely linezolid (approved 2000), 
daptomycin (approved 2003), retapamulin (approved 2007), fidaxomicin (approved 
2010) and bedaquiline (approved 2012). (Source: Butler et al, 2013)  
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2.2 Anti-infective 
 Acknowledging the challenges faced by pharmaceutical industries in antibiotic 
discovery programmes and the difficulties in keeping up with the rapidly evolving 
microbial resistance (Ewbank & Zugasti, 2011), non-antibiotic-based approaches are 
proposed as alternative therapeutic options to address the current needs for effective 
treatment against infectious diseases. These alternative therapies include vaccines, 
probiotic therapy, phage therapy, immune stimulation and virulence factor 
neutralization (Butler et al, 2013).  
 The possible next-generation anti-infective with mode of action via immune 
stimulation or virulence factor attenuation has become the spotlight of scientific 
attention (Bhavsar & Brown, 2006; Arvanitis et al, 2013). The development of anti-
infective that capitalizes on mechanism to improve host immune defense or disrupt 
pathogen virulence factor is a conceivable strategy in combating pathogenesis 
(Bhavsar & Brown, 2006; Pirofski & Casadevall, 2006; Hamill et al, 2008).  
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Table 2.1: Examples of anti-infective strategies.  
Strategies Mode of action Natural products / 
compound 
Application References 
Attenuation of 
virulence factor 
Anti-Quorum Sensing (QS) 
activity 
 
Cinnamaldehyde analog Against Vibrio 
spp. 
Brackman et al, 
2011 
 Attenuation  of pyocyanin 
production 
Raloxifene Against P. 
aeruginosa  
Ho Sui et al, 2012 
 
 
 Inhibition of 
staphyloxanthin 
 
Indole and derivatives (7-
benzyloxyindole) 
Against S. aureus Lee at al, 2013 
 Inhibition of biofilm 
formation 
 
CCG-203592 Against S. aurues Ma et al, 2012 
Immunomodulation p38 MAPK pathway and 
transcription factor ATF-7 
 
RPW-24 Small molecule Against P. 
aeruginosa 
 
Pukkila-Worley et 
al, 2012 
 Immunomodulation of lys-7 Swietenia macrophylla 
extract 
Against P. 
aeruginosa 
 
Dharmalingam et al, 
2012 
 p38 MAPK pathway and β-
catenin signaling pathway 
 
Probiotic Lactobacillus 
NCFM 
Against Gram 
positive bacteria 
Kim et al, 2012 
 Microbiota-induced immune 
protection via p38 MAPK 
pathway 
Non-pathogenic soil 
bacteria B. megaterium and 
P. mendocina 
Against P. 
aeruginosa 
 
Montalvo-Katz et al, 
2013 
 
- 11 - 
 
Strategies Mode of action Natural products / 
compound 
Application Reference 
Immunomodulation 
and attenuation of 
virulence factor 
Induction of lysozyme, 
thaumatin and saponin;  
Attenuated production 
level of lipase, protease 
and pyocyanin 
 
Tasco®  Ascophyllum 
nodosum extract 
Against P. 
aeruginosa 
 
Kandasamy et al, 
2012 
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2.3 Host – pathogen interaction study  
The host - pathogen interaction best describes the strategies evolved by both 
the host and microbes to outcompete each other in the rally to survive. The host 
harnesses immunity system encompassing at least three major responses, namely 
pathogen recognition, immune signaling triggering and immune effectors responses to 
ward-off pathogen infection (Mallo et al, 2002; Gravato-Nobre and Hodgkin, 2005; 
O’Rourke et al, 2006). On the other hand, pathogens have as well deployed a repertoire 
of evasion and invasion strategies to subvert host immune barriers, including the 
interference of host signaling pathway and the suppression of host immune effectors 
(Tan, 2001; Kurz & Ewbank, 2003; Finlay & McFadden, 2006; Evans et al, 2008). 
Thus, the study of host – pathogen interaction at cellular and molecular level could 
provide better understanding of these underlying mechanisms, including the 
evolutionarily conserved immune signaling pathways (i.e.: which signaling pathways 
are involved and what are the transcriptional changes?) and the host-specificity of 
microbial pathogenesis (i.e.: what are the virulence factors deployed by pathogen? Are 
these host-specific or universal virulence factors?). These valuable insights could then 
be expanded into drug development for the discovery of novel antimicrobials (Rahme 
et al, 1995; Garvis et al, 2009).  
The establishment of experimental host – pathogen system using invertebrate 
host has then become a rapid emerging research themes such as Arabidopsis thaliana, 
Drosophila melanogaster (Jennings, 2011) and Caenorhabditis elegans (Tan et al, 
1999) to facilitate the genetic dissection of the underlying mechanism (Kim et al, 2002; 
Schlaich, 2011). These invertebrate model organisms often share several advantages 
over the mammalian models, including economical experimental setting, ease of 
genetic manipulation and amenability for high-throughput techniques without raising 
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ethical concerns intrinsic to vertebrate animal research (Zhou et al, 2011). These 
invertebrate models could not completely replace mammalian model as preclinical 
model to predict drug safety in human, it is however useful for preliminary research to 
address fundamental questions and valuable as a quick platform for discovery purpose, 
such as gene function study and pioneer medical research (Kaletta & Hengartner, 
2006).     
The evolutionarily conservation of genetic and biochemical pathways between 
invertebrates and mammalian models are useful for drug discovery programs that 
define disease models based on a molecular basis. The introduction of C. elegans – 
pathogen interaction model (Tan et al, 1999) had made use this simple non-vertebrate 
model organism to facilitate the understanding of pathogenesis and innate immunity. 
Despite bridging the knowledge gap between the in vitro assays and mammalian model, 
C. elegans – pathogen interaction model can also be expanded as a cost-effective and 
rapid screening tool for novel antimicrobial agents, in which the drug-and-target 
interaction can be interpreted in vivo for intervention efficacy and mechanism of action 
study (Kaletta & Hengartner, 2006; Arvanitis et al, 2013).  
Model organisms are important in modeling biological question during 
preliminary research phase. Through the understanding of mechanisms and function 
at a simple level i.e.: invertebrate organism, this fundamental knowledge could be 
extended to a more complex level like mammalian models. Through the in-depth study 
of innate immunity of a diverse species, the understanding of evolutionarily conserved 
mechanisms could help researchers to explore further into evolutionary origins and 
molecular mechanisms, which ultimately could lead to the therapeutic advances in 
human research (Kim et al, 2002).  
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2.4 Caenorhabditis elegans as model organism 
Since the introduction of C. elegans by Sydney Brenner in 1960’s as the model 
organism to study animal behavior and development, C. elegans has been actively 
researched to address various important biological questions (Brenner, 1974). C. 
elegans is a simple multicellular, transparent microscopic nematode (about 1mm in 
adult size) that offers several experimental advantages as model organism. Although 
C. elegans is a relatively simple microorganism, it contains about 1000 somatic cells 
with highly differentiated anatomy such as muscles, epidermis nervous system, gonad 
and gastrointestinal tract. Under normal growth condition in laboratory, C. elegans 
feeds on E. coli OP50 and are maintained on agar medium in Petri dish. The population 
consists of hermaphrodite predominantly, with only 0.1% being male in the wild-type 
population (Figure 2.3). A self-fertilizing hermaphrodite worm can give rise to 300 
progeny whereas a male-fertilized hermaphrodite could produce up to 1000 progeny 
(Strange, 2006). This feature is particularly unique for genetics study (e.g.: mutation 
research), whereby a self-fertilizing hermaphrodite could yield a homozygous 
population without the caveat for crossing.   
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Figure 2.3: The morphology of hermaphrodite and male nematode. The 
arrowhead (top panel) indicates the vulva of a hermaphrodite while the arrow 
(bottom panel) indicates the male nematode with fan-like tail. (Source: 
Jorgensen & Mango, 2002) 
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The short generation time of C. elegans (about 2.5 days from an embryo to a 
fertile adult) offers a rapid experimental manipulation (Figure 2.4). With an average 
lifespan of 3 – 4 weeks under optimal laboratory condition, this feature also facilitates 
the study of developmental biology, embryogenesis and post-embryonic development 
within a short period. Indeed, the mapping of cell lineage during embryogenesis and 
post-embryonic has been made available (Sulston & Horvitz, 1977; Sulston et al, 1983). 
In addition, the transparent worm body also permits real-time observation of cellular 
processes. Upon the introduction of Green Fluorescent Protein (GFP) as an expression 
reporter, biological activities can now be studied without any invasive methods in the 
context of an intact living organism (Corsi, 2006). Furthermore, gene knockdown 
technique through RNA-interference (RNAi) that can be easily achieved through 
microinjection or feeding delivery method also facilitates gene function study in C. 
elegans (Hull & Timmons, 2004; Boutros & Ahringer, 2008).  
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Figure 2.4: The life cycle of C. elegans. The nematode undergoes four larval 
stages from L1 to L4 before they turn into gravid adult worms. The number 
within bracket indicates the development timing for each stage.  (Source: 
Jorgensen & Mango, 2002) 
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With its genome completely sequenced by 1998, C. elegans has provided a 
wealth of bioinformatics resources to the scientific communities, which can be 
accessed online at http://www.wormbase.org (Corsi et al, 2015). With these intrinsic 
characteristics and advantages, C. elegans proves to be a relatively cost-effective and 
yet a powerful model organism in multiple fields of biological research, such as 
neurobiology, developmental, aging and genetics study (Ewbank & Zugasti, 2011; 
Portal-Celhay et al, 2012). More recently, C. elegans has been introduced into 
microbial pathogenesis and host innate immunity research, and expanded to drug 
discovery program.    
2.5 C. elegans features as model for immunity study   
Being the soil dweller in the wild, C. elegans is susceptible to a wide range of 
pathogen, including bacteria and fungi. However, it appears that C. elegans depends 
solely on their genetically-encoded innate immunity as defense mechanisms; this 
lacking of an adaptive immune system nevertheless allows the study of innate 
immunity without the complication of adaptive immunity.  
Three major mechanisms are described for C. elegans immune defense against 
invading agents (Engelmann & Pujol, 2010). Firstly, the avoidance behavior that 
involves olfactory sensory to trigger nematode aversive response from noxious 
pathogen. Research finding suggested that C. elegans can discriminate and avoid 
noxious bacterial food source through “odour learning” in an asymmetric 
chemosensory neurons-dependent manner. This behavioral avoidance thus prevents 
nutrients uptake from potential pathogenic source and greatly minimizes the exposure 
to lethal risk factor. The second line of defense is the worm cuticle that serves as a 
resilient physical barrier against invading pathogens. This chitinous worm exoskeleton 
provides strong resistance towards puncturing, avoiding open wound for pathogen 
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invasion. As C. elegans ingests bacteria as its nutrition source, the pharyngeal grinder 
also function as a defensive barrier in which ingested bacteria can be destroyed through 
mechanical disruption. Lastly, the inducible innate immunity that involves complex 
signaling cascades to regulate the expression and secretion of immune effectors, such 
as lectins, lysozymes, antibacterial factors for pathogen clearance (Engelmann & Pujol, 
2010; Marsh and May, 2012).  
Under laboratory growth condition, infection-like condition can be achieved in 
this bacterophagus C. elegans by substituting the relatively innocuous bacterial food 
source, E. coli OP50 with the desired choices of pathogen, such as P. aeruginosa (Tan 
et al, 1999), E. faecalis (Garsin et al, 2001; Sifri et al, 2002), Staphylococcus aureus 
(Sifri et al, 2003; Bae et al, 2004), Salmonella enterica (Aballay and Ausubel, 2001; 
Tenor et al, 2004), Burkholderia pseudomallei (O'Quinn et al., 2001; Gan et al., 2002) 
and Serratia marcescens (Kurz et al., 2003). With this introduction of pathogen 
invasion through feeding delivery, C. elegans intestinal gut is the major interface 
where infection takes place for most known human pathogens, although with some 
exceptions whereby the primary infection sites are at C. elegans vulva, anus or 
epidermal cuticle (Figure 2.5). 
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Figure 2.5: Example of pathogens that can infect C. elegans and the infection 
routes by pathogens. Asterisk (*) denotes the pathogen that produces toxin to 
kill host. Most known human pathogens colonize and persist within C. elegans 
intestinal gut to establish infection. (Source: Engelmann & Pujol, 2010) 
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The effectiveness of C elegans immunity and pathogenesis can be assessed by 
studying the function of C. elegans survival over infection time. The progression of 
motility, physiological and immunesenescence, pathogen burden within C. elegans 
can be easily examined non-invasively. Following the complete sequencing of C. 
elegans genome made available in 1998, C. elegans homologs have been identified for 
about 60-80% of human genes (Corsi, 2006; Mondoux et al, 2010). Remarkably, 
approximately 40% genes associated with human disease appears to have homologs in 
C. elegans genome (Corsi, 2006). More importantly, C. elegans are also susceptible to 
most human pathogens (Kirienko et al, 2013), further supporting C. elegans as a 
suitable model to study infectious disease at genetic and molecular basis. This 
sequenced genome also offers C. elegans amenability in genetic manipulation to 
generate a large mutant library, in which hypersensitive or resistant mutant strains are 
available for research.    
Since the first description of P. aeruginosa as an infection model (Tan et al, 
1999), C. elegans has become a facile in vivo model to facilitate host-pathogen 
interaction studies such as E. faecalis (Garsin et al, 2001; Sifri et al, 2002), 
Staphylococcus aureus (Sifri et al, 2003; Bae et al, 2004), Salmonella enterica 
(Aballay et al., 2000; Aballay and Ausubel, 2001; Tenor et al, 2004; Tenor et al, 2008), 
Burkholderia pseudomallei (O'Quinn et al., 2001; Gan et al., 2002) and Serratia 
marcescens (Kurz et al., 2003). The experimental systems, most if not all, involve the 
intestinal infection of C. elegans with human microbial pathogen (Shivers et al, 2008).  
With these strikingly high degree of conservation of biochemical pathways between 
nematodes and human, C. elegans – pathogen experimental system has become an 
ideal model in uncovering novel drug targets (Giacomotto and Segalat, 2010).  By 
varying choices of pathogen, microarray and candidate gene studies reported the 
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pathogen-specific gene expression changes within C. elegans upon infection (Evans et 
al, 2008), facilitating the identification of antimicrobial effectors in C. elegans.  
2.6 Lysozyme 
The bacteriolytic phenomenon may have been described earlier than we 
thought. However, the discovery of this lytic element was only first introduced as 
“lysozyme” by Alexander Fleming in early 1922 (Laschtschenko, 1909; Rettger & 
Sperry, 1912; Fleming, 1922).  
Lysozymes are ubiquitously present in numerous phylogenetically diverse 
forms of life, ranging from virus, fungi to plants and animals (Schulenburg & 
Boehnisch, 2008). Lysozyme is characterized by its ability to hydrolyse β-1,4-
glycosidic linkages between N-acetylmuramic (NAM) and N-acetylglucosamine 
(NAG) in peptidoglycan of bacterial cell walls. Owing to this bacteriolytic bioactivity, 
lysozyme is widely recognized as an important immune effector against various 
invading pathogens. In mammals, lysozymes constitute a key component in the first 
line of defense whereby they are found in mucosal and epithelial secretion such as 
tears, saliva, milks and mucus (Bachali et al, 2002; Callewaert and Michiels, 2010).  
Lysozymes are also present in the organs of ruminants (true stomach) and marine 
bivalves (digestive gland and gills), displaying their functional diversity as digestive 
enzymes, in addition to their primary immune function (Bachali et al, 2002; Van 
Herreweghe & Michiels, 2012). This secondary function is further suggested as an 
intracellular effector of ruminants to digest and exploit gastrointestinal microbes for 
nutrition, despite to prevent the uncontrolled microbial growth within intestine (Nickel 
et al, 1998).  
